口服左旋多巴反应的昼夜差异。
Diurnal differences in response to oral levodopa.
作者信息
Frankel J P, Pirtosek Z, Kempster P A, Bovingdon M, Webster R, Lees A J, Stern G M
机构信息
Department of Neurology, Middlesex and University College Hospitals School of Medicine, London.
出版信息
J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):948-50. doi: 10.1136/jnnp.53.11.948.
Abstract
Diurnal differences in duration and quality of motor response to levodopa are frequently described by patients. The quality and duration of motor responses were objectively assessed to morning and afternoon oral levodopa doses in five patients with Parkinsonian motor fluctuations who complained of diurnal variation in response to their normal levodopa medication. Results suggest that under controlled conditions which eliminated the effects of diet and overlapping levodopa effects the response to levodopa remained unchanged throughout the day, and that the duration of response could be predicted by plasma levodopa levels.
摘要
患者经常描述左旋多巴运动反应的持续时间和质量存在昼夜差异。对五名患有帕金森病运动波动且抱怨其正常左旋多巴药物反应存在昼夜变化的患者，客观评估了其对早晨和下午口服左旋多巴剂量的运动反应的质量和持续时间。结果表明，在消除饮食和左旋多巴重叠效应影响的受控条件下，左旋多巴的反应在一天中保持不变，并且反应持续时间可以通过血浆左旋多巴水平预测。
相似文献
1
Diurnal differences in response to oral levodopa.口服左旋多巴反应的昼夜差异。
J Neurol Neurosurg Psychiatry. 1990 Nov;53(11):948-50. doi: 10.1136/jnnp.53.11.948.
2
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa.左旋多巴/卡比多巴液剂和片剂的血浆左旋多巴及运动反应波动情况
Mov Disord. 1994 Jul;9(4):463-5. doi: 10.1002/mds.870090416.
3
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.息宁与阿他美（通用名卡比多巴/左旋多巴）的药代动力学比较：一项单剂量研究。
Mov Disord. 1996 Jul;11(4):427-30. doi: 10.1002/mds.870110412.
4
Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.
Mov Disord. 1992;7(3):244-8. doi: 10.1002/mds.870070310.
5
Severe evening dyskinesias in advanced Parkinson's disease: clinical description, relation to plasma levodopa, and treatment.晚期帕金森病的严重夜间异动症：临床描述、与血浆左旋多巴的关系及治疗
Mov Disord. 1994 Mar;9(2):173-7. doi: 10.1002/mds.870090208.
6
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.帕金森病患者在使用常规和控释左旋多巴-卡比多巴联合制剂后血浆中左旋多巴及其主要代谢产物的水平。
Eur Neurol. 1993;33(1):69-73. doi: 10.1159/000116905.
7
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.接受标准左旋多巴治疗出现反应波动的帕金森病患者使用控释卡比多巴/左旋多巴（CR）：临床及药代动力学观察
Neurology. 1989 Nov;39(11 Suppl 2):88-92; discussion 95.
8
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa.左旋多巴-卡比多巴肠凝胶的药代动力学：变异性低于口服左旋多巴-卡比多巴。
J Parkinsons Dis. 2017;7(2):275-278. doi: 10.3233/JPD-161042.
9
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial.比较口服溶菌酶/左旋多巴（Parcopa）与传统口服卡比多巴/左旋多巴：一项单次、双盲、双模拟、安慰剂对照、交叉试验。
Mov Disord. 2010 Dec 15;25(16):2724-7. doi: 10.1002/mds.23158.
10
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.盐酸多奈哌齐与左旋多巴/卡比多巴联合用于帕金森病患者：多次口服给药后药代动力学变化及安全性评估
Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x.
引用本文的文献
1
Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.IPX066 的群体药代动力学：一种卡比多巴-左旋多巴的口服延长释放胶囊制剂，和伴有晚期帕金森病患者的即刻释放卡比多巴-左旋多巴。
J Clin Pharmacol. 2013 May;53(5):523-31. doi: 10.1002/jcph.63. Epub 2013 Feb 20.
2
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.帕金森病治疗中的药代动力学优化：最新进展
Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001.
3
Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.用于治疗帕金森病的药物的临床药代动力学和药效学特性。
Clin Pharmacokinet. 2002;41(4):261-309. doi: 10.2165/00003088-200241040-00003.
4
Diurnal effects of motor activity and fatigue in Parkinson's disease.帕金森病中运动活动和疲劳的昼夜效应。
J Neurol Neurosurg Psychiatry. 1993 Aug;56(8):874-7. doi: 10.1136/jnnp.56.8.874.
本文引用的文献
1
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.帕金森病中的“开-关”现象。与左旋多巴吸收和转运的关系。
N Engl J Med. 1984 Feb 23;310(8):483-8. doi: 10.1056/NEJM198402233100802.
2
Ontogeny of diurnal rhythms of central dopamine, serotonin and spirodecanone binding sites and of motor activity in the rat.
Life Sci. 1983 Jul 4;33(1):31-8. doi: 10.1016/0024-3205(83)90708-7.
3
Behavioral and neurochemical effects of apomorphine in the cat.阿扑吗啡对猫的行为和神经化学影响。
Eur J Pharmacol. 1982 Jun 4;80(4):295-309. doi: 10.1016/0014-2999(82)90074-7.
4
Dietary therapy for motor fluctuations in Parkinson's disease.
Arch Neurol. 1987 Nov;44(11):1119-21. doi: 10.1001/archneur.1987.00520230009005.
5
Diurnal responsiveness to apomorphine.对阿扑吗啡的昼夜反应性。
Neurology. 1987 Jul;37(7):1250-3. doi: 10.1212/wnl.37.7.1250.
6
Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies.帕金森病的运动波动：发病机制与治疗研究
Ann Neurol. 1987 Oct;22(4):475-9. doi: 10.1002/ana.410220406.
7
Does an inhibitory action of levodopa contribute to motor fluctuations?
Neurology. 1988 Oct;38(10):1553-7. doi: 10.1212/wnl.38.10.1553.
8
Subcutaneous apomorphine in parkinsonian on-off oscillations.皮下注射阿扑吗啡治疗帕金森病的开关现象
Lancet. 1988 Feb 20;1(8582):403-6. doi: 10.1016/s0140-6736(88)91193-2.
9
Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease.帕金森病中左旋多巴的外周药代动力学及运动反应持续时间
J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):718-23. doi: 10.1136/jnnp.52.6.718.
10
The effect of dietary protein on the efficacy of L-dopa: a double-blind study.
Neurology. 1989 Apr;39(4):549-52. doi: 10.1212/wnl.39.4.549.
Zotero 插件